Tracheobronchial Drug Exposure Should Not Be Confused with Parenchymal Target Achievement for Nebulized Amikacin - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Tracheobronchial Drug Exposure Should Not Be Confused with Parenchymal Target Achievement for Nebulized Amikacin

  • By

  • Guofu Mao

  • Haizhen Lan

  • April 29, 2026

Share

  • 1

    Tracheobronchial drug exposure should be distinguished from parenchymal target achievement for nebulized amikacin.

  • 2

    The study by Gregoire et al. measured tracheal aspirate, not infected pulmonary parenchyma, which is crucial for interpreting results.

  • 3

    Tracheobronchial exposure is relevant for preventing ventilator-associated pneumonia but less so for treating established pneumonia.

  • 4

    Future trials should differentiate between prophylactic and treatment strategies for inhaled antibiotics to improve study design.

  • 5

    Pharmacokinetic endpoints must include site-relevant measures beyond tracheal aspirate to assess effective target-site exposure.

Original Source(s)

Tracheobronchial Drug Exposure Should Not Be Confused with Parenchymal Target Achievement for Nebulized Amikacin

  • by Guofu Mao, Haizhen Lan

  • April 29, 2026

Related Content

Cough Audio Recognition for Early Detection of Respiratory Diseases: Algorithm Development and Validation Study

Higher Steroid Exposure Linked to Systemic Adverse Events in CRSwNP

Higher annual oral corticosteroid exposure was associated with greater odds of systemic adverse events, with avascular bone necrosis and pneumonia showing dose-dependent associations with cumulative dose and osteoporosis associated with longer annual exposure duration.

Top 10 CDC Updates Physicians Should Know

Recent CDC advisories, testing updates, and immunization recommendations highlight developments in infectious diseases, immunization, and diagnostic testing relevant to physicians across multiple specialties.